Trifarotene: A Current Review and Perspectives in Dermatology
Retinoids have numerous applications in inflammatory, dyskeratotic, and oncohematology diseases. Retinoids have now reached the fourth generation, progressively reducing toxicity whilst increasing their efficacy. Trifarotene is a new fourth-generation retinoid with a selective action on RAR-γ. In th...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/3/237 |
| _version_ | 1797395133469032448 |
|---|---|
| author | Terenzio Cosio Monia Di Prete Roberta Gaziano Caterina Lanna Augusto Orlandi Paolo Di Francesco Luca Bianchi Elena Campione |
| author_facet | Terenzio Cosio Monia Di Prete Roberta Gaziano Caterina Lanna Augusto Orlandi Paolo Di Francesco Luca Bianchi Elena Campione |
| author_sort | Terenzio Cosio |
| collection | DOAJ |
| description | Retinoids have numerous applications in inflammatory, dyskeratotic, and oncohematology diseases. Retinoids have now reached the fourth generation, progressively reducing toxicity whilst increasing their efficacy. Trifarotene is a new fourth-generation retinoid with a selective action on RAR-γ. In this review, we reported the trials—both concluded and in progress—including the use of trifarotene in dermatological diseases. Studies were identified by searching electronic databases (MEDLINE, EMBASE, PubMed, Cochrane, Trials.gov) from 2012 to today and reference lists of respective articles. Only articles published in English language were included. Randomized trials evaluating trifarotene tolerability, safety, and efficacy in congenital ichthyosis and acne have demonstrated great results and mild side effects, leading to the approval by the FDA of trifarotene for the treatment of lamellar ichthyosis in 2014, and of acne vulgaris in October 2019. No high-quality randomized clinical trials have evaluated the treatment of primary cutaneous lymphomas with trifarotene. Finally, we are hypothesizing future perspectives in the treatment of non-melanoma skin cancers, fungal infections, photoaging, and hand-foot skin reactions with trifarotene. |
| first_indexed | 2024-03-09T00:30:01Z |
| format | Article |
| id | doaj.art-f09054b2bc6c458fb4c5b6387336653d |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T00:30:01Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-f09054b2bc6c458fb4c5b6387336653d2023-12-11T18:37:12ZengMDPI AGBiomedicines2227-90592021-02-019323710.3390/biomedicines9030237Trifarotene: A Current Review and Perspectives in DermatologyTerenzio Cosio0Monia Di Prete1Roberta Gaziano2Caterina Lanna3Augusto Orlandi4Paolo Di Francesco5Luca Bianchi6Elena Campione7Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyAnatomic Pathology Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyMicrobiology Section, Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyAnatomic Pathology Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyMicrobiology Section, Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyRetinoids have numerous applications in inflammatory, dyskeratotic, and oncohematology diseases. Retinoids have now reached the fourth generation, progressively reducing toxicity whilst increasing their efficacy. Trifarotene is a new fourth-generation retinoid with a selective action on RAR-γ. In this review, we reported the trials—both concluded and in progress—including the use of trifarotene in dermatological diseases. Studies were identified by searching electronic databases (MEDLINE, EMBASE, PubMed, Cochrane, Trials.gov) from 2012 to today and reference lists of respective articles. Only articles published in English language were included. Randomized trials evaluating trifarotene tolerability, safety, and efficacy in congenital ichthyosis and acne have demonstrated great results and mild side effects, leading to the approval by the FDA of trifarotene for the treatment of lamellar ichthyosis in 2014, and of acne vulgaris in October 2019. No high-quality randomized clinical trials have evaluated the treatment of primary cutaneous lymphomas with trifarotene. Finally, we are hypothesizing future perspectives in the treatment of non-melanoma skin cancers, fungal infections, photoaging, and hand-foot skin reactions with trifarotene.https://www.mdpi.com/2227-9059/9/3/237acnecongenital ichthyosisT cell lymphomaRAR-γ agonistretinoidtrifarotene |
| spellingShingle | Terenzio Cosio Monia Di Prete Roberta Gaziano Caterina Lanna Augusto Orlandi Paolo Di Francesco Luca Bianchi Elena Campione Trifarotene: A Current Review and Perspectives in Dermatology Biomedicines acne congenital ichthyosis T cell lymphoma RAR-γ agonist retinoid trifarotene |
| title | Trifarotene: A Current Review and Perspectives in Dermatology |
| title_full | Trifarotene: A Current Review and Perspectives in Dermatology |
| title_fullStr | Trifarotene: A Current Review and Perspectives in Dermatology |
| title_full_unstemmed | Trifarotene: A Current Review and Perspectives in Dermatology |
| title_short | Trifarotene: A Current Review and Perspectives in Dermatology |
| title_sort | trifarotene a current review and perspectives in dermatology |
| topic | acne congenital ichthyosis T cell lymphoma RAR-γ agonist retinoid trifarotene |
| url | https://www.mdpi.com/2227-9059/9/3/237 |
| work_keys_str_mv | AT terenziocosio trifaroteneacurrentreviewandperspectivesindermatology AT moniadiprete trifaroteneacurrentreviewandperspectivesindermatology AT robertagaziano trifaroteneacurrentreviewandperspectivesindermatology AT caterinalanna trifaroteneacurrentreviewandperspectivesindermatology AT augustoorlandi trifaroteneacurrentreviewandperspectivesindermatology AT paolodifrancesco trifaroteneacurrentreviewandperspectivesindermatology AT lucabianchi trifaroteneacurrentreviewandperspectivesindermatology AT elenacampione trifaroteneacurrentreviewandperspectivesindermatology |